June 22, 2017: Santhera’s Raxone^® Receives First Positive EAMS Scientific Opinion from UK’s MHRA in Duchenne Muscular Dystrophy

May 19, 2017: Santhera Provides Update on Timeline for Application of Raxone^® in Duchenne Muscular Dystrophy in Europe

May 16, 2017: Santhera to Present Data and Host Symposium on Pulmonary Function in Duchenne Muscular Dystrophy at the American Thoracic Society 113th Annual Conference

May 09, 2017: Scottish Medicines Consortium Approves Santhera's Raxone^® (idebenone) for Restricted Use in Patients with LHON within NHS Scotland

May 02, 2017: Santhera Signs Distribution and Supply Agreement for Raxone^® (idebenone) with Pharmathen for Greece and Cyprus

April 25, 2017: Santhera becomes Founding Member of the Industry Advisory Council of the United Mitochondrial Disease Foundation

April 04, 2017: Santhera’s Shareholders Approve all Board Proposals at Annual Shareholders’ Meeting

March 07, 2017: Santhera Delivered Solid Performance in 2016 and Advances All Programs

February 10, 2017: Santhera Successfully Places CHF 60 million Senior Convertible Bonds

February 10, 2017: Santhera Launches Senior Convertible Bond Issue

January 31, 2017: Santhera Nominates New Board Members for Election at Upcoming Annual Shareholders’ Meeting

January 26, 2017: Santhera Reports Preliminary Key Financial Figures for 2016 and Provides Corporate Update

MP3 File

January 25, 2017: Santhera Announces Combination of Two Shareholder Groups

January 20, 2017: Santhera to Report 2016 Preliminary Key Financial Figures and Provide Corporate Update on January 26, 2017